高コレステロール血症の世界市場レポート 2025年

高コレステロール血症市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR14.2％で317億米ドルに成長します。予測期間中の成長は、診断やスクリーニングの改善、政府の取り組みや健康施策、危険因子の有病率の増加、市販（OTC）コレステロール低下製品の入手可能性の増加、コレステロール関連リスクに対する意識の高まりなどの要因によるものと考えられます。主要動向としては、脂質プロファイリングの進歩、ロボット支援手術の利用、ドラッグデリバリーにおけるナノテクノロジーの応用、遠隔医療プラットフォームの台頭、リポタンパク標的への注目などが挙げられます。

心血管疾患の有病率の増加は、今後数年間の高コレステロール血症市場の成長を促進すると予想されます。心血管疾患（CVD）は、心臓や血管に影響を及ぼす疾患群です。心血管疾患の増加は、不健康な食生活、運動不足、肥満率の増加、慢性的なストレス、高齢化、高血圧や糖尿病などの疾患の蔓延によるところが大きいです。高コレステロール血症治療は、LDLコレステロール値を下げ、動脈内のプラーク蓄積を減らし、血流を改善し、心臓発作、脳卒中、その他の心血管合併症のリスクを減少させることにより、心血管疾患患者を支援します。例えば、2024年10月に米国疾病予防管理センターが発表したところによると、米国では毎年約80万5,000人が心臓発作を経験しており、そのうち60万5,000人が初発で、20万人が心臓発作の既往歴のある人です。そのため、心血管疾患の罹患率の増加は、高コレステロール血症市場を促進すると予想されます。

高コレステロール血症市場の主要参入企業は、治療効果を高め、患者のコンプライアンスを向上させるために、3剤併用薬などの革新的な製品を開発しています。トリプルコンビネーションドラッグは、3つの有効成分を錠剤やカプセルなどの単一の剤形に配合したものです。例えば、2025年2月、韓国の製薬会社セルトリオン社が高血圧・高脂血症治療アムロゼット錠を発売しました。この薬は、高血圧症のカルシウム拮抗薬であるアムロジピン、コレステロールを下げるスタチン系のロスバスタチン、腸でのコレステロール吸収を抑えるエゼチミブの3つの有効成分を配合しています。本薬は4つの用法・用量（5/5/10mg、5/10/10mg、10/5/10mg、10/10/10mg）があり、アムロジピンでは高血圧症と心筋虚血に、ロスバスタチンとエゼチミブの組み合わせでは主要な高コレステロール血症に、また慢性安定狭心症または血管痙攣性狭心症の緩和にも適応があります。さらに、冠動脈疾患が証明されている患者において、狭心症による入院や心臓手術のリスクを軽減するのにも役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の高コレステロール血症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の高コレステロール血症市場：成長率分析
• 世界の高コレステロール血症市場の実績：規模と成長、2019～2024年
• 世界の高コレステロール血症市場の予測：規模と成長、2024～2029年、2034年
• 世界の高コレステロール血症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の高コレステロール血症市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 遺伝性
• 後天性
• 世界の高コレステロール血症市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• スタチン
• 胆汁酸樹脂
• ナイアシン
• PCSK9阻害剤
• コレステロール吸収阻害剤
• フィブリン酸誘導体
• その他
• 世界の高コレステロール血症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 注射剤
• 世界の高コレステロール血症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• その他流通チャネル
• 世界の高コレステロール血症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 在宅ヘルスケア
• その他
• 世界の高コレステロール血症市場、遺伝性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ヘテロ接合性家族性高コレステロール血症
• ホモ接合性家族性高コレステロール血症
• 世界の高コレステロール血症市場、後天性のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 一次高コレステロール血症
• 二次高コレステロール血症

第7章 地域別・国別分析

• 世界の高コレステロール血症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の高コレステロール血症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 高コレステロール血症市場：競合情勢
• 高コレステロール血症市場：企業プロファイル
  • Pfizer Inc.
  • Merck & Co Inc.
  • Abbvie Inc.
  • Bayer AG
  • Sanofi S.A.

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc（GSK）
• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Aegerion Pharmaceuticals Inc.
• Fresenius Kabi AG
• Sun Pharmaceutical Industries Ltd.
• Chiesi Farmaceutici S.p.A.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Ionis Pharmaceuticals Inc.
• Melinta Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 高コレステロール血症市場、2029年：新たな機会を提供する国
• 高コレステロール血症市場、2029年：新たな機会を提供するセグメント
• 高コレステロール血症市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions such as diabetes or hypothyroidism.

The primary types of hypercholesterolemia are genetic and acquired. Genetics refers to the study of genes, heredity, and the variation of inherited traits in living organisms, which play a crucial role in determining susceptibility to various conditions, including familial hypercholesterolemia. Treatment for hypercholesterolemia includes statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other medications. These treatments are available in oral and injectable forms. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other outlets, and are used by a wide range of end users, including hospitals, specialty clinics, home healthcare providers, and others.

The hypercholesterolemia market research report is one of a series of new reports from The Business Research Company that provides hypercholesterolemia market statistics, including hypercholesterolemia industry global market size, regional shares, competitors with a hypercholesterolemia market share, detailed hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. This hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $16.30 billion in 2024 to $18.66 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, including the rise of health campaigns, increased investment in research and development, a growing emphasis on preventive healthcare, and the expansion of preventive health screenings alongside lifestyle modifications.

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $31.70 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to factors such as improved diagnosis and screening, government initiatives and health policies, the growing prevalence of risk factors, the increasing availability of over-the-counter (OTC) cholesterol-lowering products, and heightened awareness of cholesterol-related risks. Key trends include advancements in lipid profiling, the use of robotic-assisted surgeries, the application of nanotechnology in drug delivery, the rise of telemedicine platforms, and the focus on lipoprotein targeting.

The growing prevalence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels. The rise in cardiovascular diseases is largely due to unhealthy diets, physical inactivity, increasing obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatments help cardiovascular disease patients by lowering LDL cholesterol levels, reducing plaque buildup in the arteries, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, the Centers for Disease Control and Prevention reported that around 805,000 people in the United States experience a heart attack each year, with 605,000 being first-time incidents and 200,000 occurring in individuals with a history of previous heart attacks. Therefore, the rising incidence of cardiovascular diseases is expected to propel the hypercholesterolemia market.

Key players in the hypercholesterolemia market are developing innovative products, such as triple-combination drugs, to improve treatment efficacy and enhance patient compliance. A triple-combination drug combines three active ingredients into a single dosage form, such as a tablet or capsule. For example, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a drug for hypertension and hyperlipidemia. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension; rosuvastatin, a statin to lower cholesterol; and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations (5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg) and is indicated for hypertension and myocardial ischemia under amlodipine, primary hypercholesterolemia under the rosuvastatin-ezetimibe combination, and also for relieving chronic stable angina or vasospastic angina. Additionally, it helps reduce the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.

In August 2023, HDL Therapeutics, Inc., a U.S.-based biotechnology company, merged with Swiftmerge Acquisition Corp. for an undisclosed amount. This merger aims to accelerate the commercialization of HDL Therapeutics' FDA-approved Plasma Delipidation System (PDS-2) for treating patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corp. is a U.S.-based special purpose acquisition company (SPAC) focused on providing treatment for HoFH.

Major players in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypercholesterolemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercholesterolemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypercholesterolemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypercholesterolemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypercholesterolemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypercholesterolemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Genetic; Acquired
• 2) By Treatment: Statins; Bile Acid Resins; Niacin; PCSK9 Inhibitors; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Other Treatments
• 3) By Route Of Administration: Oral; Injectable
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Others Distribution Channel
• 5) By End User: Hospitals; Specialty Clinics; Home Healthcare; Others End Users
• Subsegments:
• 1) By Genetic: Heterozygous Familial Hypercholesterolemia; Homozygous Familial Hypercholesterolemia
• 2) By Acquired: Primary Hypercholesterolemia; Secondary Hypercholesterolemia
• Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Abbvie Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypercholesterolemia Market Characteristics

3. Hypercholesterolemia Market Trends And Strategies

4. Hypercholesterolemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hypercholesterolemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypercholesterolemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypercholesterolemia Market Growth Rate Analysis
• 5.4. Global Hypercholesterolemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypercholesterolemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypercholesterolemia Total Addressable Market (TAM)

6. Hypercholesterolemia Market Segmentation

• 6.1. Global Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic
• Acquired
• 6.2. Global Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Bile Acid Resins
• Niacin
• PCSK9 Inhibitors
• Cholesterol Absorption Inhibitors
• Fibric Acid Derivatives
• Other Treatments
• 6.3. Global Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.4. Global Hypercholesterolemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Others Distribution Channel
• 6.5. Global Hypercholesterolemia Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• Others End Users
• 6.6. Global Hypercholesterolemia Market, Sub-Segmentation Of Genetic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heterozygous Familial Hypercholesterolemia
• Homozygous Familial Hypercholesterolemia
• 6.7. Global Hypercholesterolemia Market, Sub-Segmentation Of Acquired, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Hypercholesterolemia
• Secondary Hypercholesterolemia

7. Hypercholesterolemia Market Regional And Country Analysis

• 7.1. Global Hypercholesterolemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypercholesterolemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypercholesterolemia Market

• 8.1. Asia-Pacific Hypercholesterolemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypercholesterolemia Market

• 9.1. China Hypercholesterolemia Market Overview
• 9.2. China Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypercholesterolemia Market

• 10.1. India Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypercholesterolemia Market

• 11.1. Japan Hypercholesterolemia Market Overview
• 11.2. Japan Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypercholesterolemia Market

• 12.1. Australia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypercholesterolemia Market

• 13.1. Indonesia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypercholesterolemia Market

• 14.1. South Korea Hypercholesterolemia Market Overview
• 14.2. South Korea Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypercholesterolemia Market

• 15.1. Western Europe Hypercholesterolemia Market Overview
• 15.2. Western Europe Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypercholesterolemia Market

• 16.1. UK Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypercholesterolemia Market

• 17.1. Germany Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypercholesterolemia Market

• 18.1. France Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypercholesterolemia Market

• 19.1. Italy Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypercholesterolemia Market

• 20.1. Spain Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypercholesterolemia Market

• 21.1. Eastern Europe Hypercholesterolemia Market Overview
• 21.2. Eastern Europe Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypercholesterolemia Market

• 22.1. Russia Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypercholesterolemia Market

• 23.1. North America Hypercholesterolemia Market Overview
• 23.2. North America Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypercholesterolemia Market

• 24.1. USA Hypercholesterolemia Market Overview
• 24.2. USA Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypercholesterolemia Market

• 25.1. Canada Hypercholesterolemia Market Overview
• 25.2. Canada Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypercholesterolemia Market

• 26.1. South America Hypercholesterolemia Market Overview
• 26.2. South America Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypercholesterolemia Market

• 27.1. Brazil Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypercholesterolemia Market

• 28.1. Middle East Hypercholesterolemia Market Overview
• 28.2. Middle East Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypercholesterolemia Market

• 29.1. Africa Hypercholesterolemia Market Overview
• 29.2. Africa Hypercholesterolemia Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypercholesterolemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypercholesterolemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypercholesterolemia Market Competitive Landscape And Company Profiles

• 30.1. Hypercholesterolemia Market Competitive Landscape
• 30.2. Hypercholesterolemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Hypercholesterolemia Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc (GSK)
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Aegerion Pharmaceuticals Inc.
• 31.8. Fresenius Kabi AG
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Chiesi Farmaceutici S.p.A.
• 31.11. Aurobindo Pharma Limited
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Lupin Limited
• 31.14. Ionis Pharmaceuticals Inc.
• 31.15. Melinta Therapeutics Inc.

32. Global Hypercholesterolemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypercholesterolemia Market

34. Recent Developments In The Hypercholesterolemia Market

35. Hypercholesterolemia Market High Potential Countries, Segments and Strategies

• 35.1 Hypercholesterolemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypercholesterolemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypercholesterolemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer